Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Inclusion Criteria: * Male or female subjects with history of mild atopic asthma between 18 and 60 years-of-age * Body mass index (BMI) between 18 and 35 kg/m\^2 * Normal or clinically acceptable physical examination (PE), clinical laboratory values, and electrocardiogram (ECG); clinically acceptable PE includes history of mild atopic asthma * Used only inhaled short-acting β2-agonists infrequently to treat asthma * No current exposure to allergens to which subject experiences asthmatic responses * No other lung disease, exacerbations of asthma or lower respiratory tract infections for at least 6 weeks prior to screening * Positive skin prick test to common aeroallergens at screening * Additional inclusion criteria apply Exclusion Criteria: * History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion; * History or current medical conditions that are contraindicated for methacholine challenge, such as myocardial infarction or stroke within previous 3 months, known cardiac disease, uncontrolled hypertension and aortic or cerebral aneurysm * Evidence of active or suspected bacterial, viral, fungal or parasitic infections within past 6 weeks * Subject has know type I/II diabetes * History of residential exposure to tuberculosis or has a positive purified protein derivative (PPD) or QuantiFERON test within 4 weeks before randomiza…